ArticlePloS one2013
Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Qualitative Superiority, Not Magnitude, of Lung-Resident CD8Immune network · 2026Article
- Article
- Article
- Vaccine Strategy That Enhances the Protective Efficacy of Systemic Immunization by Establishing Lung-Resident Memory CD8 T Cells Against Influenza Infection.Immune network · 2023Article
- Review
- Review
- Article
- A "Prime and Deploy" Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T cells.Immune network · 2021Article
- Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.Vaccines · 2020Review
- Harnessing Cross-Reactive CD8Viral immunology · 2020Article
- Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.Virologica Sinica · 2019Article
- Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus.Clinical and experimental vaccine research · 2019Article
- Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts.PloS one · 2018Article
- Vaccine approaches conferring cross-protection against influenza viruses.Expert review of vaccines · 2017Review
- Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus.Scientific reports · 2016Article
- Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice.PloS one · 2016Article
- Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.Microbial cell factories · 2015Article
- Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.Plant cell reports · 2015Article
- Advancements in the development of subunit influenza vaccines.Microbes and infection · 2015Review
- Adenovirus-based vaccines against avian-origin H5N1 influenza viruses.Microbes and infection · 2015Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza vaccines that target the highly variable surface glycoproteins hemagglutinin and neuraminidase cause inconvenience of having vaccination every year. For this reason, development of universal vaccines targeting conserved viral components is needed. In this study, we generated recombinant adenovirus (rAd) vaccine encoding nucleoprotein (NP) of A/PR/8/34 influenza virus, designated rAd/NP. BALB/c mice were immunized intranasally or sublingually with rAd/NP vaccine and subsequently challenged with lethal doses of heterologous as well as homologous influenza viruses. We found that intranasal immunization of rAd/NP elicited strong mucosal IgA responses as well as stronger CD8 T-cell responses toward immunodominant K(d)-restricted NP147-155 epitope than sublingual immunization. Importantly, only single intranasal but not sublingual immunization of rAd/NP provides potent protection against both homologous and heterologous influenza virus challenges. These results suggest that recombinant rAd/NP could be a universal vaccine candidate for mucosal administration against influenza virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.